<DOC>
	<DOCNO>NCT00717756</DOCNO>
	<brief_summary>This study determine whether lenalidomide activity patient advance liver cancer growth cancer sorafenib .</brief_summary>
	<brief_title>Lenalidomide Advanced Hepatocellular Cancer : A Phase II Trial</brief_title>
	<detailed_description>This study determine response rate toxicity lenalidomide second line treatment patient liver cancer progress sorafenib .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Pathologically confirm HCC triple phase CT consistent HCC patient know cirrhosis AFP &gt; 200 ng/ml . 2 . Disease amenable curative surgical resection 3 . Patients must previously treat sorafenib . Patients unable receive sorafenib due financial reason also eligible . 4 . All previous cancer therapy , include radiation , hormonal therapy surgery , must discontinue least 4 week prior treatment study . 5 . No previous thalidomide . 6 . Patients must radiologically assessable tumor . 7 . ECOG performance status 02 study entry . 8 . Understand voluntarily sign informed consent form . 9 . Age &gt; 18 year time signing informed consent form . 10 . Able adhere study visit schedule protocol requirement . 11 . Laboratory test result within range : Absolute neutrophil count &gt; 1000/mm3 Platelet count &gt; 60,000/mm3 Serum creatinine &gt; 2.0 mg/dL Total bilirubin &gt; 4 mg/dL AST ( SGOT ) ALT ( SGPT ) &gt; 5 x ULN . 12 . Females childbearing potential ( FCBP ) â€  must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour start lenalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . See Appendix : H Risks Fetal Exposure , Pregnancy Testing Guidelines Acceptable Birth Control Methods , AND also Appendix : F Education Counseling Guidance Document 13 . Disease free prior malignancy &gt; 2 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Use experimental drug therapy within 28 day baseline . 5 . Known hypersensitivity thalidomide . 6 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 7 . Any prior use lenalidomide . 8 . Concurrent use anticancer agent treatment . 9 . Known positive HIV . ( The effect immune modulation lenalidomide patient HIV positive unknown ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>liver cancer , second line</keyword>
</DOC>